The Weight Loss Podcast | Podcast in RSS.com

The Weight Loss Podcast

The Weight Loss Podcast

di Bob Weigert & Julie Almandine

Moda e bellezza Nutrizione

Stagione 5

GLP1 Improving Heart Health

We discuss the latest news around GLP1 especially as it relates to heart health!

Rapid evolution of GLP-1: A Comprehensive Update

Discussing the rapid changes happening in the GLP-1 market. An update on everything we know so far.

Ethics and Accessibility of GLP-1ra Long Term

Discussion on the Ethics of Access, especially for lower income populations looking for weight loss solutions, and the economic feasibility of long-term access for many.

What This 2024 Presidential Election Means for GLP-1ra and Big Pharma

Today we discuss how the election of Donald J. Trump to the white house as the 47th president of the United States impacts all the stuff we talk about on this podcast: Big Pharma, Weight Loss, GLP1 Medications, Regulations. We also talk about his team: Vivek Ramaswamy, Elon Musk, and others.

Stagione 4

GLP1s - a deeper dive into how they work

Let's really do a deep dive on the mechanisms of GLP1 that we haven't touched on previously. This is going to be a discussion for our long-time followers since we skip past a lot of introductory stuff.

Current trends in weight loss: What's going on? What's the big picture?

Discussion about all the latest gossip on weight loss from around the country.

FDA reverses decision to halt compounding of Terzepetide, for now

Discussing the FDAs recent reversal on compounding Terzepitide while they re-evaluate the shortage situation. This and more on today's episode.

Big Pharma Grilled on GLP1 Pricing; Why are Ozempic and other drugs so expensive?

You don't want to miss this episode! Today, we're looking into GLP1 pricing and how congress is putting BigPharma on the hotseat trying to understand why their drugs cost so much. All that and more on today's episode.

Novo Nordisk pushes FDA to stop GLP1 compounding citing "complexity'

Today we discuss a major development: Novo Nordisk, the company behind WeGovy and Ozempic, is pushing the FDA to stop compounding pharmacies from manufacturing the compounded medications, citing the complexity of manufacture. Critics say it is just a ploy to secure profits.

featured sponsor episode: tune-health

Today we're going to do a deep dive into our sponsor and look at the services they offer and how they differ from other services in this space.

1 di 5